Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
-
Randomized Controlled Trial Comparative Study
Immunogenicity and safety of intradermal influenza vaccination in healthy older adults.
Influenza vaccine immunogenicity is suboptimal in older persons. Intradermal (ID) vaccination may be a promising alternative to intramuscular (IM) vaccination. ⋯ Influenza vaccine at 60% dose by either IM or ID route elicited antibody responses generally similar to full-dose IM vaccination among healthy elderly persons (ClinicalTrials.gov identifier: NCT00504231).
-
Case Reports
Intravenous zanamivir for patients with pneumonitis due to pandemic (H1N1) 2009 influenza virus.
We report on 2 critically ill patients with pneumonitis and acute respiratory distress syndrome due to pandemic (H1N1) 2009 influenza A virus who were treated with intravenous zanamivir and had favorable clinical outcomes. Zanamivir given intravenously may be a therapeutic option in patients with critical illness and mechanical ventilation.